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Abstract 
Background: The brain barriers establish compartments in the central nervous system (CNS) that significantly differ 
in their communication with the peripheral immune system. In this function they strictly control T-cell entry into the 
CNS. T cells can reach the CNS by either crossing the endothelial blood–brain barrier (BBB) or the epithelial blood-
cerebrospinal fluid barrier (BCSFB) of the choroid plexus (ChP).
Objective: Analysis of the cellular and molecular mechanisms involved in the migration of different human  CD4+ 
T-cell subsets across the BBB versus the BCSFB.
Methods: Human in vitro models of the BBB and BCSFB were employed to study the migration of circulating and 
CNS-entry experienced  CD4+ T helper cell subsets (Th1, Th1*, Th2, Th17) across the BBB and BCSFB under inflamma-
tory and non-inflammatory conditions in vitro.
Results: While under non-inflammatory conditions Th1* and Th1 cells preferentially crossed the BBB, under inflam-
matory conditions the migration rate of all Th subsets across the BBB was comparable. The migration of all Th subsets 
across the BCSFB from the same donor was 10- to 20-fold lower when compared to their migration across the BBB. 
Interestingly, Th17 cells preferentially crossed the BCSFB under both, non-inflamed and inflamed conditions. Barrier-
crossing experienced Th cells sorted from CSF of MS patients showed migratory characteristics indistinguishable 
from those of circulating Th cells of healthy donors. All Th cell subsets could additionally cross the BCSFB from the 
CSF to ChP stroma side. T-cell migration across the BCSFB involved epithelial ICAM-1 irrespective of the direction of 
migration.
Conclusions: Our observations underscore that different Th subsets may use different anatomical routes to enter 
the CNS during immune surveillance versus neuroinflammation with the BCSFB establishing a tighter barrier for T-cell 
entry into the CNS compared to the BBB. In addition, CNS-entry experienced Th cell subsets isolated from the CSF of 
MS patients do not show an increased ability to cross the brain barriers when compared to circulating Th cell subsets 
from healthy donors underscoring the active role of the brain barriers in controlling T-cell entry into the CNS. Also we 
identify ICAM-1 to mediate T cell migration across the BCSFB.
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Background
Central nervous system (CNS) homeostasis is guaran-
teed by the endothelial, epithelial and glial brain barriers. 
The endothelial blood–brain barrier (BBB) is localized to 
the wall of small CNS blood vessels. The epithelial blood 
cerebrospinal fluid barrier (BCSFB) is surrounding the 
choroid plexuses localized in all brain ventricles. Last 
but not least the glia limitans composed by the parenchy-
mal basement membrane and astrocyte end feet is sur-
rounding the entire CNS parenchyma at the surface (glia 
limitans superficialis) and towards the blood vessels (glia 
limitans perivascularis) [1].
The brain barriers protect the CNS from the chang-
ing milieu of the blood stream but also strictly con-
trol immune surveillance of the CNS [2]. Brain barriers 
breakdown and uncontrolled immune cell infiltration 
into the CNS are early hallmarks of multiple sclerosis 
(MS), the most common neuroinflammatory disorder in 
young adults that can lead to severe disability. Immune 
cell infiltration across the BBB is tightly regulated by the 
sequential interaction of adhesion or signaling molecules 
on immune cells and the BBB endothelium [3]. Less is 
known about the mechanisms regulating immune cell 
migration across the BCSFB. Current knowledge about 
the molecular mechanisms mediating immune cell traf-
ficking across brain barriers are mainly derived from 
experimental autoimmune encephalitis (EAE) (reviewed 
in [3]), an animal model of MS. EAE has allowed to 
develop efficient therapies targeting immune cell traffick-
ing across the BBB for the treatment of relapsing–remit-
ting MS (RRMS) [4]. Unfortunately these therapies are 
associated with progressive multifocal leukoencephalop-
athy (PML) caused by the infection of CNS cells with the 
JC virus [5]. This suggests that the current therapeutic 
strategies besides successfully inhibiting the migration of 
pathogenic immune cells into the CNS also interfere with 
CNS immune surveillance. This underscores the urgent 
need to improve our understanding of the anatomi-
cal routes and molecular mechanisms used by different 
immune cell subsets to enter the CNS.
While the etiology of MS remains unknown recent 
genome-wide association studies (GWASs) under-
scored the involvement of  CD4+ T helper (Th) cells in 
MS pathogenesis [6, 7].  CD4+ T cells are divided into 
several subsets, which are defined by lineage-specifying 
transcription factors, expression of signature cytokines 
and distinct chemokine receptors allowing these T cells 
to exert different effector functions and to migrate to 
different tissues. For instance, Th1 cells express T-bet, 
secrete IFN-γ, allowing them to help macrophages to 
eliminate intracellular viruses and bacteria, and preferen-
tially express CXCR3; Th2 cells express GATA-3, produce 
IL-4, IL-5, and IL-13, which are relevant for eliminating 
extracellular parasites, and preferentially express CCR3 
and CCR4; classical Th17 cells express RORγt, produce 
IL-17A, IL-17F, and IL-22, making them efficient helpers 
for eliminating extracellular bacteria and fungi, and pref-
erentially express CCR6 [8]. The  CCR6+ Th cell subset 
comprises also cells producing IFN-γ or IFN-γ and IL-17, 
defined as Th1* [8, 9].
Th1, Th17, and Th1* cells have been suggested to be 
involved in MS pathogenesis. However, the degrees of 
their disease involvement as well as the cellular and 
molecular mechanisms they use to enter the CNS remain 
incompletely understood. IFNγ and IL-17 are elevated in 
the CSF of MS patients, especially during the active phase 
of the disease, and are also found in the CNS parenchyma 
of post-mortem tissue of MS patients [10–12]. Besides 
Th1 cells and Th17 cells, Th1* cells (expressing both 
T-bet and RORγt, and CXCR3 and CCR6 [13]) are found 
in the CSF during early disease, in post-mortem MS 
brain tissues [9, 12, 14] and in autoproliferating T cells, 
which are enriched for brain-homing  CD4+ T cells [15]. 
Interestingly the Th17/Th1 ratio of CNS infiltrating cells 
determines lesion localization within the CNS in the EAE 
model [16, 17], suggesting that these different effector 
T-cell subsets may enter the CNS via different pathways 
resulting in different localization of the CNS lesions. In 
fact, the different  CD4+ T cell subsets express character-
istic sets of chemokine receptors (Th1:  CXCR3+, Th1*: 
 CXCR3+,  CCR6+, Th2:  CCR4+, Th17  CCR6+,  CCR4+), 
which may allow them to use different anatomical routes 
for CNS entry. Observations in EAE [18–21] have shown 
that Th17 cells preferentially enter the brain via the cho-
roid plexus in a CCR6/CCL20 dependent manner [19] 
and require lymphocyte function-associated antigen 1 
(LFA-1) but not α4-integrins [18]. In contrast, Th1 cells 
preferentially infiltrate the spinal cord by crossing the 
BBB using α4β1-integrins [20, 21]. If the different abili-
ties of mouse Th1 and Th17 to cross the BBB versus the 
BCSFB translates to human Th cell subsets has not been 
explored.
To investigate if different human  CD4+ Th subsets 
display different abilities to cross the BBB versus the 
BCSFB during CNS immune surveillance and neuroin-
flammation, we here employed human stem cell-derived 
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brain-like endothelial cells (BLECs) and a human choroid 
plexus papilloma cell line (HIBCPP) as in  vitro models 
of the BBB and BCSFB, respectively. Both BLECs and 
HIBCPP cells have previously been shown to phenocopy 
characteristics of a functional BBB and BCSFB, respec-
tively. BLECs and HIBCPP form mature adherens and 
tight junctions, show low permeability to small molecular 
tracers, establish high electrical resistance, show func-
tional expression of characteristic transporters and efflux 
pumps and display apical/basolateral polarity [22–31]. 
In addition, both human brain barrier models were pre-
viously shown by us and others to show cytokine induc-
ible expression of adhesion molecules and to be suitable 
for studying immune cell trafficking across the BBB and 
BCSFB in  vitro [26, 28, 32–34]. Using different Th sub-
sets isolated from the blood of healthy donors or from 
the CSF of MS patients, we directly compared the migra-
tion of circulating and CNS entry experienced Th1, Th1*, 
Th2 and Th17 cells across BLECs and HIBCPP monolay-
ers under inflammatory or non-inflammatory conditions 
in vitro. Our data underscore that different Th-cell sub-
sets use different cellular and molecular cues to cross the 
BBB and BCSFB and that neuroinflammation will impact 
on these mechanisms. Understanding Th-cell subset spe-
cific mechanisms of CNS entry bears the hope for devel-
oping safer therapies that specifically block the migration 
of pathogenic T cells into the CNS, while leaving the 
migration of T cells responsible for CNS immune surveil-
lance unaffected.
Material and methods
Human in vitro BBB model
The French Ministry of Higher Education and Research 
approved the protocol regarding the use of human tis-
sues and cells (CODECOH Number DC2011-1321). 
All patients gave their consents. BLECs were used 
as a human in  vitro BBB model exactly as described 
before [22, 28, 32]. In brief,  CD34+ cells were isolated 
from human umbilical cord blood and differentiated to 
endothelial cells in ECM basal medium (ScienCell) sup-
plemented with 20% (v/v) fetal bovine serum (FBS; Life 
Technologies) and 50  ng/mL of  VEGF165 (PeproTech 
Inc.). To induce a BBB phenotype,  CD34+ cell-derived 
endothelial cells were cultured on Matrigel-coated filter 
inserts (PC membrane, pore size 3.0  μm; Costar, 3402) 
for 7  days and then co-cultured with bovine pericytes 
at bottom for 6  days allowing them to differentiate into 
brain-like endothelial cells (BLECs) as described [32]. 
For transendothelial electrical resistance (TEER) meas-
urements,  CD34+ cell-derived endothelial cells were 
cultured on 0.4  μm pore filter (PC membrane, Costar, 
3401) and start co-culture with bovine pericytes at the 
same day. TEER was measured using a Volt-Ohm-Meter 
(Millicell ERS-2, MERSSTX01-electrode). In order to 
calculate the net resistance in Ω × cm2 of the cell mon-
olayers, TEER value of an empty filter was subtracted 
from each measurement and TEER values in Ohm were 
multiplied by the surface area of the filters (1.12 cm2) as 
follows. TEER (Ohm × cm2) = (cell monolayer resistance 
− empty Transwell filter resistance) × surface area  (cm2).
Human in vitro BCSFB model
Approval was obtained by the local ethics committee of 
the Medical Faculty of Mannheim, Heidelberg University 
(2009-327N-MA). HIBCPP cells derived from a human 
choroid plexus papilloma were used as a human in vitro 
BCSFB model as described [26, 34]. In brief, HIBCPP 
cells were cultured in a T75 flask using HIBCPP medium 
(DMEM/F12 (1:1) supplied with 15 mM HEPES (Gibco), 
4  mM  l-Glutamine (Gibco), 1% Penicillin and Strepto-
mycin (Gibco), 0.05% human Insulin solution (Sigma-
Aldrich), and 10% heat inactivated fetal bovine serum). 
Once HIBCPP cells reached 80% confluency, cells were 
ready to be used for starting either the inverted or stand-
ard culture models of the human in vitro BCSFB model. 
Medium was changed every two days and only HIBCPP 
cells between passages 21 and 38 were employed.
For inverted culture models, HIBCPP cells were 
seeded on non-coated inverted  Millicell® filters (pore 
size 5.0 μm, pore density 2.0 × 106 pores per  cm2, growth 
area 0.33 cm2; Millicell, MCMP24H48) with a density of 
1.0 × 105 cells/mL (day 0). Twenty-four hours after seed-
ing (day 1)  Millicell® filters were inverted and HIBCPP 
medium was added to both upper and bottom compart-
ments. Transepithelial electric resistance (TEER) was 
measured for each  Millicell® filter from day 3 until day 6 
as described above. When TEER values increased above 
70 Ω × cm2, culturing medium was changed to HIBCPP 
medium containing 1% FBS allowing to improve barrier 
characteristics, as previously described [23, 34]. HIBCPP 
monolayers were used for permeability or transmigration 
assays at day 6 when TEER values were ≥ 500 Ω × cm2.
For standard culture models, HIBCPP cells were 
seeded on the upper part of the  Millicell® filters (Milli-
cell #MCMP24H48) with a density of 1.7 × 105 cells/mL 
(day 0). Twenty-four hours after seeding (day 1) HIBCPP 
medium with 10% FBS was exchanged and added respec-
tively, on the upper and bottom compartment. The fol-
lowing steps from day 3 to day 6 of the standard culture 
model were identical to the inverted culture model.
Investigation of cell surface expression of adhesion 
molecules by flow cytometry
BLECs were cultured on 3 μm pore filter (PC membrane, 
Costar, 3402) as described above and before [32]. HIB-
CPP cells were cultured with HIBCPP-medium with 10% 
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FBS in T12.5 flasks at 37 °C (5%  CO2) until reaching 80% 
confluency. BLECs and HIBCPP cells were stimulated 
or not prior to the experiment with 1 ng/mL of recom-
binant human TNF-α (R&D systems, 210TA) and 20 IU/
mL recombinant human IFN-γ (R&D systems, 285IF) 
for 16 h at 37 °C (5%  CO2). After stimulation, cells were 
washed once with HBSS supplied with 25  nM HEPES 
and gently detached with Accutase (Innovative cell 
technology) at 37  °C (5%  CO2). Cells were washed and 
resuspended in FACS-buffer (DPBS (1×), 2.5% FBS, 1% 
 NaN3). Then 2 × 104 cells per well were transferred to a 
96-well microtiter plate and then incubated 20 min on ice 
with the fluorochrome-conjugated antibodies or respec-
tive isotype controls (Table 1). After staining, cells were 
washed twice with DPBS and measured with an Attune 
NxT Flow Cytometer (Thermofisher Scientific, Switzer-
land). Data were analyzed using FlowJoTM 10 software 
(Tree Star, Ashland, OR, USA).
Immunofluorescence stainings
Live BLECs and HIBCPP cells were incubated with 
10  µg/mL of antibodies against intercellular adhesion 
molecule-1 (ICAM-1, R&D System, clone BBIG, BBA3), 
ICAM-2 (FITZGERALD, clone CBR-IC2/2, 10R-7606), 
or vascular cell adhesion molecule-1 (VCAM-1, R&D 
system, AF809), for 20 min at 37 °C. After washing twice 
with DPBS, cells were fixed in 1% (w/v) formaldehyde 
and permeabilized in Triton X-100 (0.1% (w/v) at room 
temperature (RT). Then cell monolayers were blocked for 
10 min with skimmed milk 5% (w/v) in PBS. For the stain-
ing of P-selectin, E-selectin, or CD99, BLECs and HIB-
CPP cells were first fixed with 1% (w/v) formaldehyde and 
permeabilized in Triton X-100 (0.1% (w/v) at RT. BLECs 
or HIBCPP cells monolayers were then incubated with 
antibodies against P-selectin (Santa Cruz, SC-19996), 
E-selectin (BioLegend, clone HAE-1f, 336002), or CD99 
(Hec2, [35]) for 1  h at RT. After washing, fluorescently 
labeled secondary antibodies (Cy™3 AffiniPure Don-
key Anti-Mouse IgG (H + L), Jackson ImmunoResearch) 
were incubated for 1  h at RT. Nuclei were stained with 
DAPI at 1  µg/mL. After three steps of washing with 
DPBS, cell monolayers on filters were mounted with 
Mowiol (Sigma-Aldrich) and analyzed with a Nikon 
Eclipse E600 microscope using the Nikon NIS-Elements 
BR3.10 software (Nikon, Egg, Switzerland).
Permeability (Pe) assay
Permeability of BLEC and HIBCPP monolayers was 
assessed by measuring the clearance of Lucifer Yellow 
(LY, Lucifer Yellow CH dilithium salt, 457.25 Da, Sigma-
Aldrich) as previously described [22, 36–38]. Briefly, 
BLECs and HIBCPP were stimulated with 1  ng/mL 
TNF-α and 20 IU/mL IFN-γ for 16 h prior to the meas-
urement. LY added to the upper compartment of the 
filter inserts at a concentration of 50 μM. For the clear-
ance experiments, the amount of fluorescent tracer dif-
fusing across the monolayers was collected from bottom 
well every 20 min for a total of 60 min, and fluorescence 
intensity was measured in a Tecan Infinite M1000 multi-
well reader (Tecan Trading AG). The clearance principle 
was used to calculate the permeability coefficient (Pe) 
and to obtain a concentration-independent transport 
parameter as previously described in detail [37]. The 
experiments were done in triplicates for each condition.
Human Th cell subsets
Human  CD4+ T cells were isolated from buffy coats 
of healthy blood donors obtained from the Swiss Red 
Table 1 Fluorophore labelled antibodies and isotype controls for FACS analysis
Antibodies Fluorophore Clone Source Cat. N. Isotype
Anti-human ICAM1 BV421 HA58 BD Biosciences 564077 m-IgG1, κ
Anti-human ICAM2 PE CBR-IC2/2 BD Biosciences 558080 m-IgG2a, κ
Anti-human VCAM1 FITC 51-10C9 BD Biosciences 551146 m-IgG1, κ
Anti-human P-selectin BV510 AC1.2 BD Biosciences 743756 m-IgG1, κ
Anti-human E-selectin APC 68-5H11 BD Biosciences 551144 m-IgG1, κ
Anti-human CD99 PE-Cy7 3B2/TA8 Biolegend 371314 m-IgG2a, κ
Isotype controls Fluorophore Clone Source Cat. N.
m-IgG1, κ APC MOPC-21 BD Biosciences 555751
m-IgG1, κ BV421 X40 BD Biosciences 562438
m-IgG2a, κ PE eBM2a Invitrogen 12-4724-42
m-IgG1, κ FITC MOPC-21 Biolegend 400108
m-IgG1, κ BV510 X40 BD Biosciences 562946
m-IgG2a, κ PE-Cy7 MOPC-173 BIolegend 400232
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Cross. Human primary cell protocols were approved by 
the Swiss Federal Office of Public Health (authorisation 
N. A000197/2 to F. Sallusto). Informed consent from 
blood donors was approved by the local ethical commit-
tee (Comitato Etico Cantonale, http://www.ti.ch/CE, 
authorization n. CE3428).  CD4+CD45RO+ T-helper 
(Th1, Th1*, Th2 and Th17) cells were isolated as pre-
viously described [39, 40] by fluorescence activated 
cell sorting according to their specific expression pat-
tern of chemokine receptors  (CXCR3+CCR4−CCR6− 
for Th1;  CXCR3+CCR4−CCR6+ for Th1*, 
 CCR4+CXCR3−CCR6− for Th2;  CCR6+CCR4+CXCR3− 
for Th17) from the peripheral blood of healthy donors 
and from the CSF of relapsing-remitting MS patients 
(Table  2). T cells were expanded for 20  days with 
periodic re-stimulation with 1  μg/mL phytohaemag-
glutinin, irradiated allogeneic peripheral blood mono-
nuclear cells, and human interleukin 2 (IL-2, 500  IU/
mL) as previously described [39–41]. This methodol-
ogy has proven to allow to keep the effector T cells in 
culture for a maximum of 4  weeks, when their viabil-
ity is reduced [41]. In the present study after 20  days 
of expansion, T cells were frozen and stored in liquid 
nitrogen until employed in the experiments. Their 
stable polarization was confirmed by flow cytom-
etry analysis for the respective chemokine receptors 
and signature cytokines and the respective signature 
cytokines: IFNγ for Th1; IFNγ + IL-17 for Th1*; IL-4 
for Th2 and IL-17 for Th17 [41]. Previous studies have 
proven suitability of these human T cell subsets in stud-
ying their biological functions including their migration 
properties [15, 28, 32, 39, 42–46]. T cells were thawed 
1  day prior to the respective experiment and labeled 
with 1  μM CellTracker™ Green (CMFDA Dye, Life 
technologies) at 37  °C (5%  CO2) for 30 min at the day 
of the experiment. After labelling, T cells were washed 
and dead cells were removed by Ficoll-Hypaque gradi-
ent (780  g, 20  min, 20  °C). T cells were washed twice 
and resuspended in migration assay medium (DMEM, 
5% FBS, 4  mM  l-Glutamine, 25  mM HEPES) in the 
appropriate concentration.
Intrinsic T‑cell migration behavior
Intrinsic T-cell migration behavior was assessed by 
letting T cells migrate for 2  h across laminin (from 
Engelbreth-Holm-Swarm murine sarcoma basement 
membrane, Sigma) coated  Millicell® filters (pore size 
5.0  μm, pore density 2.0 × 106 pores per  cm2, growth 
area 0.33  cm2, Millicell, MCMP24H48). In brief, filters 
were coated with 50 μg/mL laminin diluted in DPBS (1×) 
for 30 min at RT and let the filter dry for 60 min at RT. 
1.5 × 105 T cells/well were added to the top compartment 
of the  Millicell® filters and allowed to migrate for 2 h at 
37  °C (10%  CO2). Migrated T cells were collected from 
the bottom compartment and counted with an Attune 
NxT Flow Cytometer by gating on CMFDA positive cells.
Transmigration assay
T-cell transmigration assay across BLECs and HIBCPP 
cells was performed exactly as previously described [32]. 
In brief, BLECs and HIBCPP cells were stimulated with 
both 1 ng/mL TNF-α and 20 IU/mL IFN-γ in the serum-
containing culture medium for 16 h. 1.5 × 105 labeled T 
helper cells (either Th1,  Th1∗, Th2, or Th17 cells) were 
added to the upper compartment and allowed to cross 
BLECs or HIBCPP cells monolayer for 8  h at 37  °C 
(10%  CO2). After 8  h transmigration, T cells were col-
lected from the bottom compartment and counted with 
the Attune NxT Flow Cytometer by gating on CMFDA 
positive cells. Each experiment was performed in trip-
licates for each condition. When using function block-
ing antibodies, HIBCPP cells were pre-incubated with 
either anti-human ICAM-1 (10  μg/mL; clone BBIG-I1 
(11C81), R&D Systems, apical side of HIBCPP cells of 
both inverted and standard culture models) or anti-
human CD99 (20 μg/mL; clone hec2 [35], basolateral side 
of HIBCPP cells of the inverted culture model), or appro-
priate isotype control antibody for 30 min at 37 °C (10% 
 CO2) before starting the TMA. T helper cells from three 
healthy donor and five MS patients were used in assays 
at least triplicate in each condition. In case the number 
of cells were insufficient, only 2–3 samples were involved.
Table 2 Characteristics of the CSF samples from MS patients





CSF (cells/μL) Total 
Protein CSF 
(mg/L)







P-1 CIS F 19 0 – 2 233 0.50 + + −
P-2 RRMS F 25 10 – 6 470 0.64 + − −
P-3 RRMS F 33 2 – 7 338 1.96 + + +
P-4 RRMS M 50 34 – 3 486 0.98 + − +
P-5 RRMS M 22 13 – 7 263 0.52 + + +
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Adhesion cell counts after transmigration assay
After transmigration assay, filters were washed twice with 
warmed HBSS and fixed with 37% formaldehyde vapor 
for 2  h at room temperature. Filters were then washed 
twice with DPBS and blocked and stained as described 
above. Antibody against VE-Cadherin (Santa Cruz, 
clone F-8, sc-9989) was used for checking the confluent 
BLECs monolayer after transmigration assay. Fluores-
cence labeled Th cells bound per pre-defined field of view 
(FOV) were analyzed by fluorescence microscopy (Nikon 
Eclipse E600) and FIJI software (Version 2.0.0, Image J, 
USA). Adhesion cells/FOV were determined by mean of 
counting two fields per filter. Assays were performed in at 
least triplicates for each condition.
Statistical analysis
Statistical analyses comprising calculation of degrees of 
freedom were done using GraphPad Prism 7 software 
(Graphpad software, La Jolla, CA, USA). Data are shown 
as the mean ± SD with 95% confidence interval (p < 0.05*, 
p < 0.01**, p < 0.001***, p < 0.0001****). To compare two 
groups, statistical significance was assessed by unpaired 
t-test, while more groups were analyzed by one-way 
ANOVA followed by Tukey’s multiple comparison test or 
two-way ANOVA followed by Tukey’s or Sidak’s multiple 
comparison test. The respective statistical methodology 
used for each assay is specified in corresponding figure 
legends.
Results
Cell surface expression of adhesion molecules on BLECs 
and HIBCPP cells
We first asked if BLECs and HIBCPP cells display 
expression of adhesion molecules described on the BBB 
and BCSFB in  vivo [3]. To this end, we performed flow 
cytometry analysis of non-stimulated (NS) or cytokine-
stimulated (1  ng/mL TNF-α + 20  IU/mL IFN-γ) BLECs 
and HIBCPP cells for the adhesion molecules ICAM-
1, ICAM-2, VCAM-1, P-selectin, E-selectin and CD99 
as these molecules have been implied to mediate T-cell 
migration across the brain barriers. BLECs stained posi-
tive for ICAM-1, ICAM-2 and CD99 under NS condi-
tions (Fig.  1a). After stimulation with pro-inflammatory 
cytokines, cell surface staining of ICAM-1 increased, 
while staining for ICAM-2 and CD99 did not change 
(Fig.  1a). To our surprise we found cell surface staining 
for P-selectin on NS and cytokine-stimulated BLECs, 
which was in part due to the release of P-selectin from 
Weibel-Palade bodies during preparation of single BLEC 
suspensions as shown by a similarly positive cell surface 
staining observed for von Willebrand factor (Fig.  1c). 
VCAM-1 and E-selectin could not be detected on non-
stimulated BLECs and were found upregulated on BLECs 
after pro-inflammatory cytokine stimulation (Fig.  1a). 
Detection of these adhesion molecules in BLECs mon-
olayers could be confirmed by performing immunofluo-
rescence stainings on BLEC monolayers (Fig. 1e).
HIBCPP cells stained positive for ICAM-1 and CD99, 
and as expected not for ICAM-2, P- and E-selectin under 
both NS and cytokine-stimulated conditions (Fig.  1b, 
d). While surface staining for ICAM-1 on HIBCPP cells 
increased upon 16  h pro-inflammatory cytokine stimu-
lation compared to NS condition, staining for CD99 
remained unchanged. HIBCPP cells did not stain positive 
for VCAM-1 (Fig. 1b). Thus, BLECs show adhesion mol-
ecule expression and upregulation as observed in  vivo, 
while HIBCPP lack expression of VCAM-1. Nevertheless, 
as HIBCPP cells stained positive for CD99 and ICAM-1, 
expressed by choroid plexus epithelial cells in  vivo they 
are still a useful model to study T-cell migration across 
the BCSFB.
Barrier characteristics of the human in vitro BBB and BCSFB 
models
We next analyzed and directly compared the barrier 
characteristics of BLECs and HIBCPP cell monolay-
ers by determining transendothelial and transepithelial 
electrical resistance (TEER) and permeability to a small 
hydrophilic tracer of the in vitro BBB and BCSFB mod-
els. We first compared TEER values of BLEC and HIB-
CPP monolayers at the date of transmigration assays. 
We found that HIBCPP cells showed higher TEER values 
(497.7 ± 82.7 Ω × cm2) compared to BLECs (90.5 ± 9.5 
Ω × cm2) (Fig. 2a) underscoring that, in their respective 
culture conditions, the BCSFB model is a tighter bar-
rier than the BLEC model. This was confirmed when 
measuring the permeability of BLEC and HIBCPP mon-
olayers for the small molecular tracer Lucifer Yellow 
Fig. 1 Adhesion molecule phenotype of BLECs and HIBCPP cells. Cell surface staining of BLECs (a) and HIBCPP cells (b) for the adhesion molecules 
ICAM-1, ICAM-2, VCAM-1, P-selectin, E-selectin and CD99 was analyzed by flow cytometry. c Cell surface staining of BLECs for the P-selectin and 
von Willebrand factor (vWF) was analyzed by flow cytometry. Isotype control, non-stimulated (NS) and 16 h pro-inflammatory cytokine-stimulated 
condition (1 ng/mL TNF-α + 20 IU/mL IFN-γ) are represented respectively in orange, blue and red in a histogram overlay. Immunofluorescence 
staining on BLECs (e) and HIBCPP cells (d) for ICAM-1 (red), ICAM-2 (red), VCAM-1 (green), P-selectin (red), E-selectin (red) and CD99 (red). Nuclei 
were stained with DAPI (blue). Each staining is representative of at least 3 independent experiment performed on 3 distinct filters. Both, NS and 
1 ng/mL TNF-α + 20 IU/mL IFN-γ stimulated conditions are shown. Scale bar = 50 μm
(See figure on next page.)
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(LY) with an average molecular weight of 0.45  kDa. In 
accordance to previous findings [47], BLECs cultured 
on 3  μm pore filter inserts showed very low perme-
ability to LY  (PeLY = 0.647 ± 0.091 × 10−3 cm/min). As 
expected, pro-inflammatory cytokine stimulation of 
BLECs significantly increased the permeability to LY 
 (PeLY = 2.643 ± 0.499 × 10−3 cm/min) (Fig.  2b). In con-
trast, paracellular permeability of the HIBCPP mon-
olayers to LY was fourfold lower than that of the BLEC 
monolayers  (PeLY = 0.156 ± 0.022 × 10−3 cm/min) and 
was not affected by pro-inflammatory cytokine stimu-
lation of the HIBCPP cells  (PeLY = 0.144 ± 0.006 × 10−3 
cm/min). Thus, both BLECs and HIBCPP cells establish 
functional BBB and BCSFB properties respectively, with 
the HIBCPP cells forming a significantly tighter barrier 
compared to BLECs as described in mouse models [29, 
48, 49].
Human CD4 Th cell subsets differ in their ability 
to cross the BBB and BCSFB
To explore if human Th cell subsets differ in their ability 
to cross the BBB and BCSFB we directly compared the 
migration of Th1, Th1*, Th2 and Th17 cells isolated from 
3 different healthy donors across BLECs and HIBCPP cell 
monolayers, respectively.
To determine if the intrinsic motility of the different 
Th cell subsets differs in a significant manner we first 
compared the spontaneous migration of Th1, Th1*, Th2 
and Th17 cells isolated from 2 different donors across 
laminin-coated filters for a period of 2  h. The sponta-
neous migration of Th1 and Th1* cells into the lower 
chamber was comparable and significantly higher when 
compared to Th17 and Th2 cells (Fig.  3a). Th2 cells 
showed the lowest intrinsic motility, which was signifi-


























































































Fig. 2 Barrier characteristics of BLECs and HIBCPP cells. a The time-dependent progression of the trans-endothelial or epithelial electrical resistance 
(TEER) of BLECs and HIBCPP cell monolayers were measured by Volt-Ohm-Meter. BLECs were seeded onto 0.4 μm pore size Costar  Transwell® 
filters and HIBCPP cells onto 5 μm pore size  Millicell® filters over a period of 6 days. Solid lines represent mean and error bars show ± SD. Data 
are representative data from at least 3 experiments each performed in triplicates. b Permeability for 0.45 kDa Lucifer Yellow (LY): BLECs were 
cultured onto 3 μm pore size Coster  Transwell® filters for 7 days as a monoculture and then co-culture with pericyte for 6 days and permeability 
was measured at day 13. HIBCPP cell were cultured onto 5 μm pore size  Millicell® filters and permeability was measured at day 6. Bars show the 
mean permeability coefficients Pe ± SD of diffused tracer across the BLECs or HIBCPP cell monolayer. Data are Representative data from at least 3 
independent experiments with three filters per conditions. Statistical analysis: Student’s t-test p < 0.05*
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To explore the ability of the different Th subsets to 
cross the BBB versus the BCSFB under inflammatory 
and non-inflammatory conditions we investigated their 
spontaneous migration across cytokine-stimulated and 
non-stimulated BLECs and HIBCPP monolayers. Under 
conditions of immune surveillance, e.g. in the absence 
of cytokine stimulation significantly higher fractions 
of Th1* cells, followed by Th1 cells crossed the BLEC 
monolayer over a period of 8  h when compared to 
Th17 and Th2 cells (Fig. 3b). This Th-cell subset specific 
migration behavior was observed for the Th cells from 
all 3 donors investigated and was different from their 
intrinsic migration behavior underscoring that differ-
ent Th subsets have different abilities to cross the BBB 
under conditions of CNS immune surveillance. Inter-
estingly, under inflammatory conditions the migration 
of all Th subsets, except for the Th2 subset, across the 
BLEC monolayer was found to be significantly reduced 
when compared to non-inflammatory conditions, and 
at the same time the migration rates for all Th subsets 
across the cytokine-stimulated BLEC monolayer were 
now comparable (Fig.  3b). This suggests that under 
inflammatory conditions the mechanisms controlling 
T-cell migration across the BBB change and apply in a 
similar fashion to all  CD4+ T-cell subsets.
Since we found reduced numbers of Th cells to 
migrate across cytokine stimulated BLECs monolay-
ers, we asked if Th cells adhere better to the inflamed 
BLECs monolayer in our experimental setting. To test 
this, we fixed and stained BLECs monolayer after the 
transmigration assay and counted firmly adhered Th 
cells on BLECs. We found that significantly higher 
numbers of Th1, Th1* and Th2 cells adhere to cytokine 
stimulated BLECs compare to non-stimulated BLECs 
(Fig.  3c). This suggests that Th cells from the periph-
eral blood of healthy donors adhere better to inflamed 
BLECs in our experimental setting and in part explain 
the reduction of transmigrated Th cells across cytokine 
stimulated BLECs.
We next investigated the ability of the identical Th sub-
sets from the same 3 healthy donors to migrate across the 
in vitro BCSFB model. In general, migration of the Th cell 
subsets from the basolateral (choroid plexus stroma-fac-
ing) side to the apical (CSF-facing) side of the HIBCPP 
monolayers was about tenfold lower when compared 
to their migration across the BLEC monolayers dur-
ing the same period of 8 h. Also, we did not observe any 
significant difference in the migration rates of Th cells 
across HIBCPP monolayers in the absence or presence 
of inflammatory stimulation, suggesting that molecular 
cues required for Th cell migration across the BCSFB do 
not change upon cytokine stimulation. The Th17 cells 
and to a lesser degree the Th1* cells from all 3 healthy 
donors were found to cross the HIBCPP monolayer in 
significantly higher fractions, when compared to Th1 and 
Th2 cells (Fig. 3d). These observations suggest that Th17 
and Th1* cells can preferentially use the BCSFB for CNS 
entry via the CSF filled ventricle and furthermore show 
that different Th cell subsets can explore different brain 
barriers for their preferential entry into the CNS.
CSF‑derived Th cell subsets from MS patients 
do not display enhanced migration across the brain 
barriers
We next asked if T-cell subsets isolated from the CSF of 
MS patients and thus experienced in migration across 
brain barriers show enhanced abilities to cross the BBB 
or BCSFB. To this end, we used expanded  CD4+ T cells 
isolated from the CSF of 5 MS patients and studied their 
migration across the BBB and BCSFB in the same man-
ner as the migration of circulating Th cells from healthy 
donors. In general, CSF derived Th cell subsets from MS 
patients did not show significantly enhanced migration 
across the BBB and BCSFB, when compared to circulating 
Fig. 3 Transmigration assay across BLECs and HIBCPP cells. a Spontaneous T-cell migration over 2 h across laminin coated 5 μm pore size  Millicell® 
filters is shown. The graph shows the percentage of transmigrated T-cells of healthy donors B (red) and C (blue). Data are displayed as the mean 
on a superimposed scatter dot plot of 4 independent experiments; 2 experiments for each donor each in triplicates. Statistical analysis: two-way 
ANOVA followed by Sidak’s multiple comparison (p < 0.05*, p < 0.0001****). b, d, e, g  CD4+ T-cell (Th1, Th1*, Th2 and Th17) migration rate across 
non-stimulated (NS) or 16 h pro-inflammatory cytokine-stimulated (1 ng/mL TNF-α + 20 IU/mL IFN-γ) BLECs and inverted HIBCPP cell monolayers 
was measured after 8 h transmigration assay. Percentages of transmigrated T cells from peripheral blood of three healthy donors (Donor A–C) 
and CSF of five MS patients (P-1–P-5) across BLECs (b, e) and inverted HIBCPP cell monolayer (d, g) are displayed. Data are shown as the mean on 
superimposed scatter dot plot of 5 or 6 independent experiments each performed in triplicates. Statistical analysis: two-way ANOVA followed by 
Tukey’s multiple comparison test within conditions (between subsets) (p < 0.05*, p < 0.01**, p < 0.001***, p < 0.0001****). Two-way ANOVA followed 
by Sidak’s multiple comparison test (NS versus stimulated condition) (p < 0.05§, p < 0.01§§, p < 0.0001§§§§). c, f The numbers of  CD4+ T-cell (Th1, Th1*, 
Th2 and Th17) adherent to BLECs monolayer after transmigration assay were displayed. Data are shown as the mean on superimposed scatter dot 
plot of 3 or 6 independent experiments each performed in triplicates. Statistical analysis: two-way ANOVA followed by Sidak’s multiple comparison 
test (NS versus stimulated condition) (p < 0.001§§§, p < 0.0001§§§§). Cells used for the representation of the endothelium, the epithelium (HIBCPP 
cells) and T cells are adapted from Servier Medical Art (http://smart .servi er.com/), licensed under a Creative Common Attribution 3.0 Generic 
License
(See figure on next page.)
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Th cell subsets from healthy donors (Fig. 3e, g). Although 
the migration rate of Th-cell subsets derived from CSF 
of MS patients was variable dependent on patients, CSF 
derived Th1* cells crossed the BLECs monolayers in 
higher numbers, when compared to Th1, Th17 and Th2 
cells in the absence of inflammatory stimuli (Fig. 3e). As 
already observed for the Th-cell subsets isolated from 
peripheral blood of healthy donors, all CSF derived Th 
cell subsets showed a similar capacity to cross the BLEC 
monolayer under neuroinflammatory conditions. Unlike 
Th cells derived from peripheral blood of healthy donors, 
only CSF derived Th 1* cells showed reduced migration 
rate across inflamed BLECs compared to non-inflam-
matory BLECs. At the same time, we found that Th cells 
derived from CSF of MS patients showed no significant 
difference of adhesion to BLECs upon inflammation 
(Fig.  3f ). When studying the migration of CSF derived 
Th cell subsets across the BCSFB, we observed the trend 
that CSF derived Th17 and Th1* cells from MS patients 
crossed the HIBCPP monolayer in higher fractions under 
both inflammatory and non-inflammatory conditions 
when compared to Th1 and Th2 cells, though it was not 
significant because of higher variability depending on the 
patient (Fig. 3g). These observations suggest that barrier 
crossing experienced Th cell subsets derived from the 
CSF of MS patients do not show a significantly increased 
ability to cross the brain barriers, when compared to Th-
cell subsets isolated from the peripheral blood of healthy 
donors. Our study therefore underscores the active role 
of the brain barriers in controling the migration of dif-
ferent Th cell subsets into the CNS during inflammatory 
and non-inflammatory conditions.
Molecular mechanisms mediating  CD4+ T cells 
across the BCSFB
We have previously shown that all  CD4+ Th-cell sub-
sets use ICAM-1 and CD99, but not platelet endothelial 
cell adhesion molecule (PECAM)-1 to cross cytokine 
stimulated BLEC monolayers under static conditions 
[32]. Here we asked if ICAM-1 and CD99 also mediate 
Th-cell migration across the BCSFB from the choroid 
plexus stroma to the CSF-facing side. Investigating the 
migration of Th cell subsets from peripheral blood of 
healthy donors across HIBCPP monolayers, we found 
that antibody-mediated blocking of epithelial ICAM-1 
significantly reduced the migration of all human Th-cell 
subsets across TNF-α/IFN-γ-stimulated HIBCPP mon-
olayers (Fig. 4b). We also found a trend towards reduced 
numbers of human  CD4+ T-cell subsets migrating across 
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Fig. 4 Molecular mechanisms mediating  CD4+ T-cell migration across HIBCPP from choroid plexus stroma side to CSF side. Percentage of 
transmigrated T-cells from peripheral blood of healthy donors B and C across 16 h pro-inflammatory cytokine-stimulated (1 ng/mL TNF-α + 20 IU/
mL IFN-γ) inverted HIBCPP cells monolayer pretreated with either anti-human CD99 blocking antibody (20 μg/mL) (a), anti-human ICAM-1 
blocking antibody (10 μg/mL) (b) or isotype control antibody are shown.  CD4+ T-cells (Th1, Th1*, Th2 and Th17) were allowed to migrate across 
inverted HIBCPP cells monolayer for 8 h and migrated cells were collected and counted. Results are standardized to isotype control (100%). Data 
are shown as the mean on superimposed scatter dot plot of 2 independent experiments each performed in triplicates. Statistical analysis: two-way 
ANOVA followed by Tukey’s multiple comparison test (p < 0.05*, p < 0.001***, p < 0.0001****). Cells used for the representation of the endothelium, 
the epithelium (HIBCPP cells) and T cells are adapted from Servier Medical Art (http://smart .servi er.com/), licensed under a Creative Common 
Attribution 3.0 Generic License
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(Fig.  4a). To confirm the efficacy of the CD99 blocking 
antibody, we compared side-by-side the effect of anti-
body mediated blocking of CD99 on Th1-cell migration 
across the BLECs and HIBCPP monolayers. This con-
firmed our previous observations on the role of CD99 in 
Th1 migration across BLECs [32] (data not shown) and 
thus efficacy of CD99 function blocking of our antibody.
At the same time, we observed that blocking ICAM-1 
comparably reduced the migration of all Th subsets 
across HIBCPP monolayers, suggesting that ICAM-1 is 
required for the migration of all Th cell subsets across 
the BCSFB. As ICAM-1 is only expressed on the api-
cal (CSF-facing) side of HIBCPP cells and therefore not 
directly available at the basolateral side for T-cell migra-
tion across the BCSFB, these results suggest that the Th 
cells may require epithelial ICAM-1 at the last step of the 
transepithelial diapedesis cascade.
CD4+ Th cells can cross the BCSFB from the CSF 
to the choroid plexus stroma side
Since a recent study has proposed that T cells may exit 
the CNS via the choroid plexus [50], we next investi-
gated if the different Th cell subsets can cross the HIB-
CPP monolayers from the apical to the basolateral side, 
thus mimicking their migration from the CSF side into 
the choroid plexus stroma. To this end, we used a stand-
ard culture system of HIBCPP cells and first tested the 
barrier characteristics of HIBCPP monolayers in this 
culture system. We found that while the TEER of HIB-
CPP monolayers was significantly higher in the standard 
culture system (640.3 ± 49.3 Ω × cm2) when compared 
to the inverted culture system (497.7 ± 82.7 Ω × cm2), 
the permeability for Lucifer yellow was comparable for 
both systems  (PeLY = 0.144 ± 0.006 × 10−3 cm/min, and 
0.156 ± 0.022 × 10−3 cm/min, respectively, for the stand-
ard and inverted culture system). We next investigated 
the migration of the different Th-cell subsets derived 
from the peripheral blood of healthy donors across the 
HIBCPP monolayers over 8 h in the presence or absence 
of prior proinflammatory cytokine-stimulation (1  ng/
mL TNF-α + 20  IU/mL IFN-γ for 16  h). In general we 
observed that the migration of the different Th-cell sub-
sets from the apical to the basolateral site of HIBCPP cell 
monolayers was significantly lower when compared to 
their migration from the basolateral to apical site of HIB-
CPP monolayers (Figs. 3d, 5a). Th17 cells showed a signif-
icantly increased ability to cross the HIBCPP monolayers 
from the apical to basolateral side, when compared to 
Th1, Th1* and Th2 cells under both, non-stimulated and 
16 h pro-inflammatory cytokine-stimulated conditions 
(Fig. 5a), exactly as previously observed when comparing 
the migration of the same Th cell subsets across HIBCPP 
monolayers from the basolateral to apical side (Fig. 3d). 
These observations underscore that low numbers of CSF 
derived  CD4+ T cells may be able to leave the CNS via 
the choroid plexus.
Therefore we finally asked if apically expressed epithe-
lial ICAM-1 mediates Th cell migration from the api-
cal to the basolateral site of the BCSFB. To this end, we 
pre-incubated standard culture HIBCPP cell monolay-
ers with anti-human ICAM-1 blocking antibodies and 
subsequently investigated the migration of Th-cell sub-
sets derived from the blood of healthy donors across the 
HIBCPP monolayer. We found that blocking of epithelial 
ICAM-1 significantly reduced the migration of all  CD4+ 
Th cell subsets across the standard culture HIBCPP cell 
monolayer to the same degree (Fig. 5b). Importantly, the 
percentage of T-cell migration across the HIBCPP cell 
monolayers was reduced fourfold more in the stand-
ard culture (Fig.  5b) when compared to T-cell migra-
tion across the inverted culture HIBCPP cell monolayers 
(Fig. 3c). This supports the notion that lack of availability 
of apical ICAM-1 interferes with the first adhesive step in 
T-cell migration from the apical to abluminal site of the 
BCSFB.
Discussion
Three main routes for  CD4+ T-cell entry into the CNS 
have been identified to date [1, 51]: from the blood via 
the choroid plexus stroma across the choroid plexus 
epithelium (BCSFB) into the CSF filled ventricles, from 
blood to the CSF filled subarachnoid space at the brain 
or spinal cord surface, and from blood to parenchymal 
perivascular spaces at the level of post capillary venules 
(BBB) [51]. Recent advances of in  vivo live cell imaging 
technique allow us to investigate dynamic interactions of 
immune cells and CNS barrier-forming endothelial cells 
[52], however, because of the preferential accessibility at 
the brain and spinal cord surface the main focus of these 
studies has been immune cell interaction with leptome-
ningeal microvessels. Thus, studying the active role of 
the BBB and BCSFB in regulating the migration of differ-
ent T-cell subsets into the CNS in vivo in its entire com-
plexity is still difficult. A further limitation may be that 
molecular mechanisms identified for immune cell cross-
ing of the BBB and BCSFB in animal models may not 
fully translate to the situation in humans.
To improve our understanding on the cellular and 
molecular mechanisms established at the endothelial 
BBB and the epithelial BCSFB that control the entry of 
different Th cell subsets into the CNS we here employed 
human in  vitro models for the BBB and the BCSFB 
and human  CD4+ T-cell subsets isolated from healthy 
donors and MS patients. We side-by-side compared the 
ability of Th1, Th2, Th17 and Th1* cells of the same 
donors in crossing the BBB and the BCSFB. Our data 
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provide in vitro evidence that human Th1 and Th1* cells 
preferentially cross the BBB under non-inflammatory 
conditions, while Th17 cells showed increased ability 
compared to the other Th subsets from the same donor 
to cross the BCSFB irrespective of the inflammatory 
state. Notably, this preferential migratory behavior of 
Th17 cells was also observed for CNS entry experienced 
Th17 cells isolated from the CSF of MS patients, sug-
gesting that the BCSFB at the level of the choroid plexus 
actively controls T-cell entry into the CNS.
There is indeed increasing evidence that the choroid 
plexus plays an important role for CNS immunity and 
immune mediated disorders such as MS. Compara-
tive transcriptome analyses from the choroid plexus 
of healthy and EAE mice showed significant increase 
in the expression of genes encoding for adhesion mol-
ecules, T-cell activation markers as well as important 
chemokines and cytokines [53, 54]. These observations 
attribute a relevant role to the choroid plexus for con-
trolling T-cell migration into the CNS during immune 
surveillance and neuroinflammatory conditions [53, 54]. 
CNS T-cell entry via the choroid plexus implies a mul-
tistep process, where initially T cells have to extravasate 
via the choroidal microvessels, which lack a BBB, reach 
the choroid plexus stroma and in a second step cross 
the BCSFB, formed by choroid plexus epithelial cells, to 
reach CSF filled ventricular spaces of the CNS. A previ-
ous report showed that circulating T cells extravasate in 
a P-selectin-dependent manner across fenestrated cap-
illaries to reach the choroid plexus stroma [55]. How-
ever, direct evidence showing how T cells located in the 
choroid plexus stroma enter the CNS is limited [49]. 
Although we here observed that the transmigration rate 
of all Th cell subsets across the HIBCPP monolayer was 
extremely low compared to BLECs, we still observed that 
all  CD4+ Th subsets could cross the HIBCPP monolay-
ers under both, non-inflammatory and inflammatory 
conditions (Fig. 3b and c). Our data thus further support 
the notion that the choroid plexus is a potential T-cell 
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Fig. 5 CD4+ T-cell migration across HIBCPP from CSF side to choroid plexus stroma side. a  CD4+ T-cell (Th1, Th1*, Th2 and Th17) migration rate 
across non-stimulated (NS) or 16 h pro-inflammatory cytokine-stimulated (1 ng/mL TNF-α + 20 IU/mL IFN-γ) standard HIBCPP cell monolayers was 
measured after 8 h transmigration assay. Percentages of transmigrated T cells from peripheral blood of two healthy donors (Donor B and C) across 
standard HIBCPP cell monolayer are displayed. Data are shown as the mean on superimposed scatter dot plot of 4 independent experiments each 
performed in triplicates. Statistical analysis: two-way ANOVA followed by Tukey’s multiple comparison test within conditions (between subsets) 
(p < 0.05*, p < 0.01**, p < 0.001***, p < 0.0001****). b Percentage of transmigrated T-cells from peripheral blood of healthy donors B and C across 
16 h pro-inflammatory cytokine-stimulated (1 ng/mL TNF-α + 20 IU/mL IFN-γ) standard HIBCPP cells monolayer pretreated with either anti-human 
ICAM-1 blocking antibody (10 μg/mL) or isotype control antibody are shown.  CD4+ T-cells (Th1, Th1*, Th2 and Th17) were allowed to migrate across 
standard HIBCPP cells monolayer for 8 h and migrated cells were collected and counted. Results are standardized to isotype control (100%). Data 
are shown as the mean on superimposed scatter dot plot of 4 independent experiments each performed in triplicates. Statistical analysis: two-way 
ANOVA followed by Tukey’s multiple comparison test. (p < 0.0001****). Cells used for the representation of the endothelium, the epithelium (HIBCPP 
cells) and T cells are adapted from Servier Medical Art (http://smart .servi er.com/), licensed under a Creative Common Attribution 3.0 Generic 
License
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surveillance and neuroinflammation. Notably, Th17 cells 
showed an increased ability to cross the BCSFB com-
pared to other Th subsets from the very same donor, 
which corresponds to our previous in vivo findings in a 
mouse model of EAE which showed that  CCR6+ Th17 
cells may preferentially enter the brain via the BCSFB to 
induce EAE [19]. We also found that significantly higher 
numbers of Th1* cells migrate across the BLEC monolay-
ers under non-inflammatory conditions compared to the 
Th subsets of the very same donors (Fig. 3b). Th1* cells 
have been found in MS lesions [12] and are more abun-
dant in the CSF compared to blood in MS patients [9]. 
Potential pathogenicity of Th1* cells is further supported 
by their pro-inflammatory phenotype by secreting IFN-
γ, IL-17 and GM-CSF [9, 12] and their identification 
as auto-proliferating  CD4+ T cells, enriched in brain-
homing cells [15]. Accumulation of Th1* cell subsets in 
peripheral blood is also observed in natalizumab-treated 
relapse-free RRMS patients, but not in natalizumab-
treated patients during a relapse [9, 15]. In fact, the latter 
study provided evidence that Th1* cells show enhanced 
migration to the brain or CSF compartments during MS 
relapses. Combined with our present findings that there 
is no difference in the ability of different Th cell subsets 
from the very same donor to cross the BBB under inflam-
matory conditions, one may speculate that the migration 
of Th1* cells across the BBB is rather relevant in the ini-
tiation phase of an MS relapse. Taken together identifica-
tion of the molecular mechanisms that mediate enhanced 
migration of Th1* cells and Th17 cells across the non-
inflamed BBB and BCSFB, respectively, may open 
avenues to specifically block CNS entry of pathogenic 
T-cell subsets and thus preventing MS relapses while 
still allowing for Th cell entry required for CNS immune 
surveillance.
While the role of adhesion molecules on BBB endothe-
lium has been studied intensively (reviewed in [3]), less 
is known about adhesion molecule expression at the 
BCSFB-forming epithelium. Data from rodent models 
show that ICAM-1 and VCAM-1 are constitutively and 
functionally expressed at the BSCFB on the apical side 
of choroid plexus epithelial cells and upregulated during 
EAE [56, 57]. However, it still remains unclear whether 
these adhesion molecules, with their exclusive polar-
ized location on the apical (CSF-facing) side of the cho-
roid plexus epithelial cells, play a relevant role in T-cell 
migration across the BCSFB from choroid plexus stroma 
to the ventricular space. We here show that antibody-
mediated blockade of epithelial ICAM-1 had a slightly 
however significantly reduced the migration of all Th 
subsets across the BCSFB from the basolateral to apical 
side (Fig. 4b). It has been previously shown that apically 
expressed ICAM-1 in intestinal epithelium contributes 
to finalization of the migration of neutrophils across this 
barrier and their sustained adhesion to the apical sur-
face of this epithelium leading to activation of epithelial 
Akt and β-catenin signaling and wound healing [58, 59]. 
Thus, apical ICAM-1 at the BCSFB may fulfill a similar 
role in guiding the final steps of T cells having crossed 
the epithelial barrier by adhesive interactions. Th cells 
expressing the ICAM-1 ligand LFA-1 might use ICAM-1 
on the apical side of the BCSFB as a molecular anchor to 
firmly adhere on the apical side of the choroid plexus epi-
thelium and to complete their transmigration from the 
choroid plexus stroma to the CSF ventricle spaces. Not 
too surprisingly we observed that function blocking of 
ICAM-1 almost abolished the low rate of migration of 
the different  CD4+ T cells observed across the choroid 
plexus epithelium from the CSF to the choroid plexus 
stroma side (Fig.  5b) underscoring the prominent role 
of ICAM-1 in mediating T-cell adhesion and potentially 
migration across the BCSFB from the apical to the baso-
lateral side.
We have previously shown that in addition to ICAM-1, 
CD99 mediates the migrations of different human  CD4+ 
T cells across the BBB endothelium in vitro [32]. Here we 
provide additional evidence that different human  CD4+ T 
cells also use ICAM-1 and possibly CD99 when crossing 
the BCSFB. It is worth to emphasize that function block-
ing of ICAM-1 or CD99 equally affected the migration of 
all  CD4+ T-cell subsets from the same donors. Further-
more, ICAM-1 was shown to mediate the migration of 
other immune cell subsets (e.g.  CD8+ T cells [60], B cells 
[61], polymorphonuclear leukocytes [62], monocytes 
[63]) across the BBB. Taken together this underscores an 
important role for ICAM-1 in CNS entry of innate and 
adaptive immune cells maintaining CNS immunity. In 
fact, Efalizumab, a monoclonal antibody targeting LFA-
1, when previously used for the treatment of psoriasis 
patients, was shown to cause high rates of PML [64, 65] 
and was thus withdrawn from the market. In contrast to 
ICAM-1, less is known about the role of CD99 in medi-
ating immune cell migration into the CNS. CD99 was 
shown to regulate the migration of monocytes [66] and 
 CD4+ T cells [32] across in vitro models of the BBB. Here 
we also found that blocking CD99 reduced the migration 
of all  CD4+ T-cell subsets across the choroid plexus epi-
thelium with to a comparable degree. These observations 
further underscore the active role of the BCSFB in con-
trolling Th cell subset entry into the CNS.
Precise involvement of chemokines or lipid media-
tors binding to G-protein coupled receptors (GPCRs) 
on the different Th cell subsets in their respective migra-
tion across the BBB and BCSFB remain to be explored. 
Engagement of GPCRs on the T cells induces inside-out 
activation of cell surface expressed adhesion molecules of 
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the integrin family allowing for the sustained firm arrest 
of T cells on the BBB [3]. Observations made by us and 
others showed that while GPCR signaling is not required 
for post-arrest crawling of effector Th cells on vascular 
endothelial cells under physiological flow, it is required 
for their diapedesis across the endothelial monolayer 
[60, 67]. Preliminary observations made with the Th cell 
subsets used in the present study confirm involvement of 
GPCR signaling in the diapedesis of all Th subsets across 
BLEC monolayers. Furthermore, our previous stud-
ies have shown that addition of exogenous CXCL12 to 
the CSF side increased T-cell migration across HIBCPP 
monolayers [31, 68, 69]. These data support the addi-
tional role for GPCR signaling in the migration of effector 
Th cell subsets across the BBB and BCSFB. The precise 
nature of the GPCR ligands involved in T cell migration 
across the BBB and BCSFB during immune surveillance 
and neuroinflammation remain to be explored.
Since the capillaries at the choroid plexus are fenes-
trated, and thus lack a BBB, immune cells located in 
the choroid plexus stroma are additionally exposed to 
peripheral stimuli [50]. Indeed, magnetic resonance 
imaging (MRI) using iron oxide magnetic nanoparticles 
combined with ex vivo histological analysis showed that 
the iron oxide particles were taken up by immune cells 
present in the choroid plexus stroma in mouse models 
of EAE or following intraperitoneal administration of 
lipopolysaccharide [70–72]. These observations suggest 
that the choroid plexus is involved in CNS immunity and 
plays and active role already during the early inflamma-
tory response. However, it is not clear if immune cells 
present in the choroid plexus stroma have previously 
entered from the blood stream of the CNS. To this end, 
we invested the migration of different Th cell subsets 
across the HIBCPP monolayers from the CSF side to cho-
roid plexus stroma side. Although their migration rates 
were very low when compared to their migration from 
the basolateral to apical side, we here provide in vitro evi-
dence that all investigated Th subsets could also migrate 
across the choroid plexus epithelium from CSF side 
to choroid plexus stroma side. Our findings are thus in 
accordance to previous observations in mouse models 
that showed that intracerebroventricularly injected acti-
vated Th1 cells could reach the choroid plexus stroma in 
an ICAM-1 dependent manner [50].
Conclusion
In conclusion, we here show that human Th cell subsets 
can cross in  vitro models of the human BBB endothe-
lium and BCSFB epithelium. Our study underscores 
that the brain barriers hereby actively control the migra-
tion of the different Th cell subsets during inflamma-
tory and non-inflammatory conditions. We also show 
that different human Th cells use different mechanisms 
to cross the BBB versus the BCSFB during immune sur-
veillance and neuroinflammatory conditions confirm-
ing previous observations in animal models [18–21]. 
Therefore, understanding the different molecular mecha-
nisms mediating the migration of different Th cell sub-
sets across the BBB and the BCSFB into the CNS during 
immune surveillance and neuroinflammation bears the 
hope for the development of therapies preferentially 
blocking CNS entry of pathogenic T cells while leaving 
CNS entry of those required for CNS immune surveil-
lance largely unaffected.
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